SCHEMBL5070808

SCHEMBL5070808

CC(C)(C)OC(=O)NC1C2CCC1Cc1cc[c]cc1C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
KDM1A O60341 2/20 0.36
MAOB P27338 1/20 0.36
CTSK P43235 2/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DRD2 P14416 2/20 0.35
BTK Q06187 1/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
KCNA3 P22001 1/20 0.34
GAA P10253 1/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL431869 0.80 EPHX2 (0.46) EPHX2NFKB1NFKB2RELAKDM1A
SCHEMBL5071764 0.78 PSEN1 (0.46) EPHX2NFKB1NFKB2RELAKDM1A
SCHEMBL5073431 0.77 PSEN1 (0.48) EPHX2NFKB1NFKB2RELAKDM1A
SCHEMBL6109560 0.75 KDM4D (0.43) EPHX2NFKB1NFKB2RELAKDM1A
SCHEMBL20262067 0.74 GAA (0.39) EPHX2NFKB1NFKB2RELAKDM1A
SCHEMBL23620470 0.74 NFKB1 (0.47) EPHX2NFKB1NFKB2RELAKDM1A
SCHEMBL9689056 0.72 DRD2 (0.49) KMT2ADRD2CKS1BSKP1SKP2
SCHEMBL6053198 0.72 DRD2 (0.46) KDM1AMAOBDRD2PSEN1PSEN2
SCHEMBL6105734 0.71 KMT2A (0.35) EPHX2NFKB1NFKB2RELAKDM1A
SCHEMBL6106276 0.71 KDM4E (0.44) EPHX2NFKB1NFKB2RELAKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365196-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK SHARP & DOHME LTD. (GB) 2008-04-29 US disclosed
EP-1268412-B1 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME (GB) 2006-11-22 EP disclosed
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK CANADA INC. (CA) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives BACE1, BACE2, PSEN2 EPHX2 1381/4885NFKB1 1694/4885NFKB2 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.